Show latest about:
Keep settings
  Freetext search
 Market prices
 Technology guide
 Real estate
 Israel in depth
RSS  feeds
  Search results
Mylan shareholders approve Perrigo takeover bid
65% of Mylan's shareholders approved the $30 billion takeover bid for Perrigo.
Globes correspondent   28 Aug 15   17:37

Macrocure share price plunges after trial failure
The Phase III clinical trial for CureXcell for treatment of venous leg ulcers is not expected to meet its main target.
Shiri Habib-Valdhorn   23 Aug 15   16:03

UBS: Copaxone sales strong despite generic rivals
UBS says, "The launch for generic Copaxone has not gone very well, with molecule share hovering around 5%."
Shiri Habib-Valdhorn   20 Aug 15   15:14

Teva to oppose Mylan's bid to take over Perrigo
Teva has a 4.6% stake in Mylan and has lost $370 million on paper on its holdings in its rival.
Shiri Habib-Valdhorn   18 Aug 15   19:16

MeMed swiftly diagnoses if a disease is viral or bacterial
The Israeli company's innovative diagnostic solutions reduce use of unnecessary antibiotics.
Chen Shalita   19 Aug 15   16:14

Teva torn between two very different types of drugs
Teva is faced with an identity crisis: generic or branded pharmaceutical company? IBI VP Elah Alkalay discusses the challenges.
Elah Alkalay    5 Aug 15   11:21

Israeli company offers new hope for treating severe depression
NeuroRX, run by brothers Jonathan and Daniel Javitt, is based on research spurred by a close friend's suicide.
Gali Weinreb    1 Jul 15   16:16

For more results from our archive, Click here.